PMID- 16837769
OWN - NLM
STAT- MEDLINE
DCOM- 20070808
LR  - 20211203
IS  - 1347-8613 (Print)
IS  - 1347-8613 (Linking)
VI  - 101
IP  - 3
DP  - 2006 Jul
TI  - Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear 
      cells.
PG  - 256-9
AB  - We evaluated the effect of alacepril, CV-11974, and spironolactone on the 
      production of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis 
      factor-alpha (TNF-alpha) in cultured human peripheral blood mononuclear cells 
      stimulated with angiotensin (Ang) II. Alacepril, CV-11974, and spironolactone 
      significantly reduced the enhanced production of MCP-1 and TNF-alpha induced by 
      exogenous Ang II. Specifically, 10 muM of spironolactone significantly reduced 
      cytokine production, compared to the same dose of alacepril or CV-11974. These 
      findings indicate that spironolactone may contribute to ameliorate the prognosis 
      of patients with cardiovascular diseases by reducing Ang II-induced inflammation, 
      although further exploration including determining the mechanisms would be 
      required.
FAU - Miura, Ryuzea
AU  - Miura R
AD  - Department of Cardiovascular Medicine, Okayama University Graduate School of 
      Medicine, Dentistry and Pharmaceutical Sciences, Japan. miura@mpc.t.u-tokyo.ac.jp
FAU - Nakamura, Kazufumi
AU  - Nakamura K
FAU - Miura, Daiji
AU  - Miura D
FAU - Miura, Aya
AU  - Miura A
FAU - Hisamatsu, Kenichi
AU  - Hisamatsu K
FAU - Kajiya, Masahito
AU  - Kajiya M
FAU - Nagase, Satoshi
AU  - Nagase S
FAU - Morita, Hiroshi
AU  - Morita H
FAU - Fukushima Kusano, Kengo
AU  - Fukushima Kusano K
FAU - Ohe, Tohru
AU  - Ohe T
FAU - Ishihara, Kazuhiko
AU  - Ishihara K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20060713
PL  - Japan
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 0 (Tetrazoles)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11128-99-7 (Angiotensin II)
RN  - 27O7W4T232 (Spironolactone)
RN  - 9G64RSX1XD (Captopril)
RN  - S8Q36MD2XX (candesartan)
RN  - X39TL7JDPF (alacepril)
SB  - IM
MH  - Adult
MH  - Angiotensin II/*antagonists & inhibitors/pharmacology
MH  - Angiotensin II Type 1 Receptor Blockers/pharmacology
MH  - Angiotensin-Converting Enzyme Inhibitors/pharmacology
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Benzimidazoles/pharmacology
MH  - Biphenyl Compounds
MH  - Captopril/analogs & derivatives/pharmacology
MH  - Cells, Cultured
MH  - Chemokine CCL2/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Leukocytes, Mononuclear/*drug effects/metabolism
MH  - Male
MH  - Mineralocorticoid Receptor Antagonists/*pharmacology
MH  - Spironolactone/*pharmacology
MH  - Tetrazoles/pharmacology
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2006/07/14 09:00
MHDA- 2007/08/09 09:00
CRDT- 2006/07/14 09:00
PHST- 2006/07/14 09:00 [pubmed]
PHST- 2007/08/09 09:00 [medline]
PHST- 2006/07/14 09:00 [entrez]
AID - JST.JSTAGE/jphs/SC0060049 [pii]
AID - 10.1254/jphs.sc0060049 [doi]
PST - ppublish
SO  - J Pharmacol Sci. 2006 Jul;101(3):256-9. doi: 10.1254/jphs.sc0060049. Epub 2006 
      Jul 13.